Overview

A Phase 3 Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This is a Phase 3, 2-arm, randomized, open-label, global, multicenter study comparing the efficacy of ripretinib to sunitinib in participants with GIST who progressed on first-line treatment with imatinib, harbor co-occurring KIT exons 11+17/18 mutations, and are without KIT exon 9, 13, or 14 mutations.

Phase:

Phase 3

Details

Lead Sponsor:

Deciphera Pharmaceuticals LLC

Treatments:

Sunitinib